

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



## EVERGRANDE HEALTH INDUSTRY GROUP

### EVERGRANDE HEALTH INDUSTRY GROUP LIMITED

恒大健康產業集團有限公司

(a company incorporated in Hong Kong with limited liability)

(Stock code: 708)

### (1) POLL RESULTS OF GENERAL MEETING HELD ON 25 FEBRUARY 2019 AND (2) SUPPLEMENTAL INFORMATION ON DISCLOSEABLE TRANSACTION

#### POLL RESULTS OF GENERAL MEETING

Reference is made to the circular of the Company dated 1 February 2019 (the “Circular”), setting out, *inter alia*, the notice of General Meeting. Unless otherwise stated, capitalised terms used herein shall have the same meanings as those defined in the Circular.

The poll results of the resolution proposed at the General Meeting are as follows:

Ordinary Resolution		Number of votes (Approximate % to the number of shares voted at the General Meeting)		Total number of votes cast
		For	Against	
a)	To approve, confirm and ratify in all respects the Integrated Insurance Procurement Agreement, and the consummation of the transactions contemplated thereunder (including the proposed annual caps) based on the terms and conditions under the Integrated Insurance Procurement Agreement (further details of which are set out in the Circular); and	678,922,069 (99.9999%)	1 (0.0001%)	678,922,070
b)	To authorize any of the directors of the Company (“ <b>Directors</b> ”) to complete and do all such acts and things or to sign or execute such other documents or supplemental agreements or to sign or execute such other documents or supplemental agreements or amendments for the Company, such Director or, as the case may be, the Board may consider necessary, desirable or expedient or in the interest of the Company to give effect to the terms of the matters contemplated under the Integrated Insurance Procurement Agreement, all transactions contemplated thereunder and all other matters incidental thereto or in connection therewith.			

\* The full text of the resolution is set out in the notice of General Meeting dated 1 February 2019.

The Board is pleased to announce that as more than 50% of the votes were cast in favour of each of the above resolution, this resolution was duly passed by the Shareholders as ordinary resolution. The Company has appointed Tricor Secretaries Limited, the share registrar of the Company, to act as the scrutineer for the purpose of vote-taking at the General Meeting.

As at the date of the General Meeting, the Company had 8,640,000,000 Shares in issue. As disclosed in the Circular, as China Evergrande and its associates have a material interest in the Integrated Insurance Procurement Agreement and the transactions contemplated thereunder, they were required to abstain and had abstained from voting on the resolution at the General Meeting. As such, the Independent Shareholders representing 2,160,450,000 Shares were entitled to attend and vote on the resolution proposed at the General Meeting. Save as disclosed above, no Shareholder was required under the Listing Rules to abstain from voting on the resolution at the General Meeting.

### **SUPPLEMENTAL INFORMATION ON DISCLOSEABLE TRANSACTION**

Reference is made to the announcement of the Company dated 29 January 2019 (the “**Announcement**”) in relation to the Group’s investment in Alpraaz AB and the establishment of Konev AB as a joint venture. Unless context requires otherwise, capitalised terms used herein shall bear the same meanings as those defined in the Announcement.

Based on the total issued share capital of the Target Company as at the date of this announcement and assuming there will be no other change to the total issued share capital of the Target Company other than pursuant to the Transaction Agreement,

- (1) upon completion on the First Closing Date, NEVS will hold approximately 5% of the issued share capital of the Target Company as enlarged by the issuance of the New Shares 1; and
- (2) further assuming first closing takes place and upon completion on the Second Closing Date, NEVS will hold in aggregate approximately 20% of the issued share capital of the Target Company as enlarged by the issuance of the New Shares 1 and New Shares 2.

For and on behalf of the Board of  
**Evergrande Health Industry Group Limited**  
**Shi Shouming**  
*Chairman*

Hong Kong, 25 February 2019

*As at the date of this announcement, the executive Directors of the Company are Mr. SHI Shouming, Mr. PENG Jianjun and Mr. QIN Liyong; and the independent non-executive Directors of the Company are Mr. CHAU Shing Yim David, Mr. GUO Jianwen and Mr. XIE Wu.*